经典的迷幻药是否会增加发作风险? 一个范围审查审查
Óscar Soto-Angona1, Adriana Fortea2, Lydia Fortea3
1Sociedad Española de Medicina Psicodélica (SEMPsi), Barcelona, Spain; Department of Psychiatry and Forensic Medicine, Universitat Autònoma de Barcelona, Barcelona, Spain; Parc Sanitari Sant Joan de Déu, Barcelona, Spain; Fundació Sant Joan de Déu, Institut de Recerca Sant Joan de Déu, Barcelona, Spain.
概括
经典的迷幻药可能不会增加健康个体的发作风险. 然而,将它们与kambo或等其他物质相结合可能会增加发作风险,这需要谨慎地解释当前的数据.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 精神病发作是使用迷幻药物的一个重要问题,导致患者在临床试验中被排除在外.
- 心理健康群体的发病率较高,这使得迷幻药辅助治疗研究复杂化.
- 了解迷幻药与精神病发作之间的关系对于安全的治疗应用至关重要.
研究的目的:
- 对有关经典迷幻药物和发作的现有文献进行范围审查.
- 综合人类和动物研究的发现.
- 识别知识缺口,并建议未来的研究方向.
主要方法:
- 使用PRISMA-ScR指南进行了全面的文献搜索.
- 搜索的数据库包括PubMed,科学网络,谷歌学者,LILACS和Scielo.
- 包括涉及人类和动物模型的研究.
主要成果:
- 总共有16项人类和11项动物研究被确定.
- 结果表明,单独的迷幻药可能不会提高健康受试者或动物的发作风险.
- 与kambo或等物质同时使用可能会增加发作风险.
结论:
- 目前的证据表明,单独使用经典迷幻药的发作风险很低.
- 由于有限的外部有效性和同时使用的物质的潜在风险,建议谨慎使用.
- 需要进一步的研究来阐明神经生物学机制并确认安全性.
相关概念视频
Hallucinogens and Psychedelics
163
Hallucinogens are psychoactive substances that profoundly alter perceptual experiences, generating unreal visual and sensory images. Often referred to as psychedelic drugs — a term derived from the Greek words "psyche" (mind) and "delos" (revealing) — these substances include marijuana and lysergic acid diethylamide (LSD), among others. These drugs vary in intensity and effects.
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
Marijuana, derived from the dried leaves and flowers of the hemp plant, contains...
163
CNS Stimulants: Psychedelic Agents
146
Hallucinogens, also known as psychedelic drugs, are a class of substances known for their ability to alter perception, cognition, and emotions. Despite their profound effects on the mind, these drugs are non-addictive, setting them apart from many other abused substances. The mechanism of action of these drugs lies in their impact on the 5-HT2A receptor in the brain. Upon activation, this receptor couples to Gq-type G proteins, triggering a cascade that releases intracellular calcium. This...
146
Antiepileptic Drugs: Potassium Channel Activators
169
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
169
Arteries of the Lower Limbs
187
Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
187
Seizures: Classification
335
Epilepsy is primarily characterized by unpredictable seizures, either provoked by an identifiable factor, such as injury or illness, or unprovoked, occurring spontaneously without apparent cause.
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
Seizures are typically classified into two main categories: focal and generalized seizures.
Focal Seizures
Focal seizures originate from specific regions of the brain. These seizures are further sub-classified into two types:
335
Electroconvulsive Therapy
31
Electroconvulsive therapy (ECT), or shock therapy, remains a critical biomedical intervention for severe, treatment-resistant depression. While its origins can be traced back to Hippocrates' observations that malaria-induced convulsions alleviated mental illness, modern ECT has evolved significantly from its earlier, more primitive applications. First introduced in 1938 by Ugo Cerletti and his colleagues, ECT involves inducing controlled seizures using electrical currents. In its early...
31


